BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
BridgeBio Pharma, Inc. (Nasdaq: BBIO) announced on April 7, 2023, that it granted restricted stock units totaling 25,900 shares to five new employees. This award was made under the company’s 2019 Inducement Equity Plan and is in compliance with Nasdaq Listing Rule 5635(c)(4). The Plan, established to attract talent, has undergone amendments since its inception in November 2019.
Founded in 2015, BridgeBio focuses on developing medicines for genetic diseases and cancers. The company operates a pipeline that spans early research to advanced clinical trials, emphasizing its commitment to genetic medicine and patient care.
- Granting of 25,900 shares attracts new talent, potentially enhancing workforce capabilities.
- The use of an Inducement Equity Plan indicates a strategic approach to employee compensation.
- None.
PALO ALTO, Calif., April 07, 2023 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today announced that on March 7, 2023, the compensation committee of BridgeBio’s board of directors granted five new employees restricted stock units for an aggregate of 25,900 shares of the Company’s common stock. All of the above-described awards were made under BridgeBio’s 2019 Inducement Equity Plan (the Plan).
The above-described awards were each granted as an inducement material to the employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4) and were granted pursuant to the terms of the Plan. The Plan was adopted by BridgeBio’s board of directors in November 2019 and has been amended and restated from time to time.
About BridgeBio Pharma, Inc.
BridgeBio Pharma, Inc. (BridgeBio) is a commercial-stage biopharmaceutical company founded to discover, create, test and deliver transformative medicines to treat patients who suffer from genetic diseases and cancers with clear genetic drivers. BridgeBio’s pipeline of development programs ranges from early science to advanced clinical trials. BridgeBio was founded in 2015 and its team of experienced drug discoverers, developers and innovators are committed to applying advances in genetic medicine to help patients as quickly as possible. For more information visit bridgebio.com and follow us on LinkedIn and Twitter.
BridgeBio Contact:
Vikram Bali
contact@bridgebio.com
(650)-789-8220
FAQ
What recent employee stock grants did BridgeBio announce?
Under which plan were the stock units granted?
What is the purpose of the Inducement Equity Plan?
What is BridgeBio Pharma focused on?